Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of FCO2 front-line therapy in chronic lymphocytic leukemia
2011-005329-27Phase 2Completed
- Sponsor
- GIMEMA
- Start
- May 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, single-arm trial of ofatumumab in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by GIMEMA. Primary endpoint: Complete response rate. Started May 2013; status: completed.
02
Drugs
ofatumumab
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2011-005329-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005329-27.